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ORIGINAL RESEARCH

Association Between Primary Care Provider Status and
Preventive Health Care Among People Who Inject Drugs
E Katherine Nenninger, MD, MPH,1 Katherine Sharp, MD, MPH,2 Bianca Bustamente,3 Kim Murray, MPP,4
Kinna Thakarar, DO, MPH5
Division of Infectious Diseases, Lifespan, Providence, RI, 2Department of Preventive Medicine, Maine Medical Center,
Portland, ME, 3College of Medicine, University of New England, Portland, ME, 4Center for Outcomes Research and
Evaluation, Maine Medical Center Research Institute, Scarborough, ME, 5Division of Infectious Diseases, Maine Medical
Center, Portland, ME
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Introduction:

People who inject drugs (PWID) are at increased risk for preventable, communicable infections, such
as hepatitis B. Preventive care, such as hepatitis B vaccination, is often delivered through primary
care providers (PCPs). However, PWID may not have access to PCPs and, therefore, may receive
preventive care through other sites. We aimed to characterize PCP and preventive care use among
PWID in Maine.

Methods:

This is a cross-sectional study of PWID hospitalized with infections associated with injection drug use
in Maine from January 2019 to May 2020. Descriptive analyses were used to identify characteristics
of participants, rates of screening, and vaccination of participants with and without PCPs. Logistic
regression analyses were performed to explore the relationship between PCP status and delivery of
preventive services for PWID. Hepatitis B vaccination was an outcome of interest.

Results:

Of 101 participants, 68 (67%) had a PCP. Overall rates of hepatitis C (93%) and HIV (85%) screening
were high and did not differ based on PCP status. More participants with PCPs had previously received
a hepatitis B vaccination (62% of those with PCPs, 33% of those without PCPs; P = .006). Only half of
those with PCPs recalled receiving a hepatitis B vaccination through a PCP office. Having a PCP was
predictive of having received the hepatitis B vaccination (adjusted odds ratio, 3.59; 95% CI, 1.27-7.58;
P = .014).

Conclusions:

Many PWID in Maine engage with PCPs and preventive care. Results from this study call for enhanced
delivery of preventive services and linkages to care for PWID.

Keywords:
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M

aine is experiencing an overdose crisis.1 In
parallel, there have been increasing rates
of injection-associated infections, such as
communicable diseases (eg, hepatitis A, B, and
C), and risk of bacterial infections (eg, cellulitis,
infective endocarditis).2-4
There are many prevention strategies to combat
these infections, including hepatitis A and B
vaccination, HIV pre-exposure prophylaxis (PrEP),
harm reduction services, and screening to identify,
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treat, and prevent community transmission.5,6 Yet,
people who inject drugs (PWID) face barriers to
accessing these services. These preventive services
are often delivered through primary care providers
(PCPs); however, some PWID have difficulty
accessing primary care due to competing priorities,
housing instability, and lack of transportation.7
Also, our health care system creates challenges
for PWID, such as inconsistencies in health care
providers, extensive wait times, and lack of provider
skill. In one study, less than 60% of primary care
residents felt that they had the ability to work with
PWID. They reported trust, relatability, compliance,
and stigma as barriers to forming an appropriate
physician-patient relationship.7,8
1
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In 2016 to 2017, researchers in Boston,
Massachusetts, found that “dehumanizing”
negative interactions with health care professionals
led PWID to postpone health care visits, conceal
information about drug use, and minimize their
pain level or symptoms. Instead, these patients
obtained care from community-based organizations
or syringe service programs (SSPs).9 Although
community-based organizations and SSPs are a
great resource for PWID that may provide harm
reduction education, disease screening, sterile drug
supplies, counseling, and linkages to care, they
are not usually designed to deliver full-spectrum
preventive care services.10
A few small studies examined whether PWID who
have PCPs are receiving preventive care from
their PCP. In 141 PWID recruited from SSPs in
Massachusetts, participants with a PCP received
more preventive services and vaccines than those
without a PCP, but they still got less than a third
of recommended care options. Only 62% informed
their PCP of their drug use, which affected how
preventive care was discussed.10 Another study
found that 75% of PWID in Denver, Colorado, and
83% of PWID in Seattle, Washington, saw their
primary care provider within the past year for an
acute problem, rather than for preventative care.
These findings show that opportunities are missed
to promote health in PWID who are already engaged
in care.11
For this study, we examined the interaction of
primary and preventive care engagement among
PWID. We chose hepatitis B vaccination as a marker
for receiving preventive services in the primary
care setting, as this vaccine can be challenging to
deliver in community or inpatient settings. Hepatitis
B vaccination requires multiple doses (2-3 doses,
depending on the formulation) over 1 to 6 months,
and, therefore, multiple clinical encounters.
In Maine, there have been alarming increases in
acute hepatitis B infections among young people,
which has been attributed to injection drug use. The
state has seen a seven-fold increase from 2012 to
2017, with 53% of cases attributed to injection drug
use.12 In 2019, the rate of acute hepatitis B cases in
Maine was the highest in the United States.13 Acute
hepatitis B can lead to hospitalization and, rarely,
fulminant liver failure.14 Though chronic infection is
less likely to develop among people who acquire
hepatitis B in adulthood, 11% of chronic infections
in Maine are attributed to injection drug use.12
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Hepatitis B is highly transmissible with limited
treatment options, and chronic hepatitis B infection
can ultimately lead to cirrhosis and hepatocellular
carcinoma.6 In addition to vaccination, risk can be
mitigated by harm reduction education and safe
injection practices. Although, and unfortunately, a
recent evaluation of harm reduction practices in this
study cohort found low rates of using safe injection
techniques.15
There are many other preventive services indicated
for PWID. Screening for HIV and hepatitis C
identifies those who need treatment and helps
prevent new cases. HIV can be prevented using
PrEP, which is indicated for PWID who have shared
injection equipment or been in a drug treatment
program within 6 months. PrEP is also indicated
for anyone who has sex with a PWID or has
multiple sexual partners with infrequent condom
use.16 Hepatitis A vaccination should be offered to
people who use injection or non-injection drugs.17
Screening for other sexually transmitted infections
and tuberculosis is recommended, as well as other
preventive services that are age-appropriate, such
as annual influenza vaccination.17 This study aimed
to examine (1) the prevalence of PCP use among
PWID in Maine, (2) whether PWID are receiving
recommended preventive services focused on viral
hepatitis and HIV, and (3) whether having a PCP
is associated with an increased odds of having
received a hepatitis B vaccination.

METHODS
Participants
Study participants included people aged 18 to
65 years who were hospitalized with infections
association with injection drug use from January
2019 to March 2020. Four hospital sites (Maine
Medical Center, Maine General, Eastern Maine
Medical Center, and Pen Bay Medical Center) in
Maine were selected from regions with a high
potential for communicable disease outbreaks.18
Insurance status included Medicare, Medicaid,
commercial, and dual insurance. Patients were
excluded if they were unable to provide consent due
to intubation, psychosis, or other reasons, or if they
had suicidal or homicidal ideations. Participants
received a $25 gift card as compensation for their
time completing the survey.
Data collection
Data were collected as part of the “Rural Harm
Reduction Access and Regional Trends (Rural
2
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Heart)” study, which is an observational cohort
study examining barriers to using syringe services
in Maine.15 Data were collected through audio
computer-assisted surveys and medical chart
review. Data were de-identified for the analysis.
Informed consent was obtained from all participants.
Data on hepatitis B infection were collected from
self-report and problem list documentation in the
electronic medical record which did not include
serologies.
Variable description
PCP use was defined as either (1) responding “yes”
to the survey question “Do you have a doctor that
you consider your primary care doctor, or main
doctor?” or (2) having a PCP listed in the electronic
medical record during hospitalization. Preventive
care was defined using self-reported and serologic
evidence of HIV and hepatitis C screening, selfreported PrEP use, and self-reported completion
of multidose vaccines or serologic evidence of
immunity. Race and sexual orientation were not
included in this analysis due to low variability.“Male”
includes cisgender male and transgender
male; “female” includes cisgender female and
transgender female. Homelessness was defined as
self-reported status of staying in a shelter or on the
street within the past 6 months, or having primary
residence in a park, vehicle, abandoned building, or
other location.Hepatitis B vaccination was defined
as either (1) self-report of receiving a full vaccine
course or (2) having documented positive hepatitis
B surface antibodies without evidence of hepatitis B
infection. Data on timing of hepatitis B vaccination,
such as pediatric or adult receipt, were not available.
Hepatitis B infection was defined as having a positive
surface antigen and/or detectable hepatitis B DNA.
A combination of self-report and laboratory data
were used in this determination because serologies
were not available for all participants, and data on
hepatitis B core antibody status were not obtained.
Hepatitis A immunity was determined by self-report
of vaccination or by hepatitis A immunoglobulin G
or total antibody positive, which could be derived
from vaccination or natural infection. Hepatitis C
exposure was defined as prior exposure to hepatitis
C, but no evidence of chronic infection. Hepatitis
C infection was defined as acute or chronic
hepatitis C infection with detectable hepatitis C
RNA. Participant age was stratified by less than
40 years or greater than or equal to 40 years.
We chose this cutoff to identify people at highest
Published by MaineHealth Knowledge Connection, 2022

risk of hepatitis B acquisition who would likely
benefit most from vaccination.12
Data analysis
We conducted a cross-sectional descriptive
analysis to examine differences in characteristics
of participants with and without PCPs, as well as
with and without hepatitis B vaccination. Variables
of interest included demographics, health care
use, infection history (focused on preventable
communicable diseases), preventive care, and
SSP use. Bivariate analysis using Student’s t-tests
and chi-square or Fischer exact tests, where
appropriate, were performed to identify associations
between having a PCP and hepatitis B vaccination.
Exploratory multivariable logistic regression was
performed to examine the association between
having a PCP and hepatitis B vaccination.
Variables for the model were chosen based on
clinical relevance (age, insurance status) and
findings from the bivariate logistic regression
analysis with P < .10 (use of SSPs). Participants
who had hepatitis B exposure or infection were not
excluded from the analysis but were considered
unvaccinated. Analyses were conducted in Stata/
IC 16, SAS (version 9.4), and R (version 3.6).
This study was approved by the MaineHealth
Institutional Review Board.

RESULTS
The study included 101 participants. Sixty-eight
participants (67%) had a PCP, most of whom
(75%, n = 51) had seen their PCP within the past
12 months. The most common reasons for not
having a PCP included cost (57%), feeling judged
in the past (27%), and not having insurance (15%).
Some participants cited multiple reasons including
“Other” reasons cited by <10% of participants which
included having old PCP, being afraid, do not need
PCP, do not know any PCP. Among participants,
85% (n = 58) with a PCP had insurance and 48%
(n = 16) without a PCP had insurance (P ≤ .001).
Seventy-one percent of participants (n = 72) were
age 18 to 39 years, and 44% (n = 44) of participants
self-identified as male and 56% (57) self-identified
as female. The cohort of patients with PCPs
contained a significantly lower percentage of males
(37%, n = 25) than those without PCPs (58%,
n = 19; P = .046) (Table 1).

3
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Table 1. Descriptive Analysis of Demographics Stratified by Primary Care Physician*

All
Age, y (range 21-58)
18-39
40+
Self-identified gender
Female
Male
Insurance status
Has insurance
No insurance
Unknown
Rurality
Rural (isolated and small rural)
Urban (large rural and metropolitan)
Housing status
Unhoused
Stable housing
Ever incarcerated
Yes
No

Abbreviations: PCP, primary care provider.

Total,
No. (%)
101

With PCP,
No. (%)
68 (67)

Without PCP,
No. (%)
33 (33)

72 (71)
29 (29)

49 (72)
19 (28)

23 (70)
10 (30)

.806

57 (56)
44 (44)

43 (63)
25 (37)

14 (42)
19 (58)

.048

74 (73)
25 (25)
2 (2)

58 (85)
8 (12)
2 (3)

16 (48)
17 (52)
0

18 (18)
83 (82)

14 (21)
54 (79)

4 (12)
29 (88)

.409

46 (46)
55 (54)

29 (43)
39 (57)

17 (52)
16 (48)

.401

90 (89)
11 (11)

60 (88)
8 (12)

30 (91)
3 (9)

1.00

Hepatitis B vaccination history was the only
preventive measure that was significantly more
common among people who had PCPs: 62%
(n = 42) of patients with a PCP had a hepatitis B
vaccine versus 33% (n = 11) of those without a
PCP (P = .006). Among the 35 patients with a PCP
who reported their vaccination location, 21 (60%)
reported vaccination at a PCP office. Twenty-two
(22%) of all participants reported that hepatitis A
and B vaccinations at SSPs had been “helpful.”
Participants were also asked about their contact
with other sites where vaccines could potentially be
administered. Ninety (89%) participants had been
incarcerated in the past, 61 (60%) had engaged
with outpatient medication for addiction treatment
in their lifetime, and 67 (66%) had ever used SSPs.
When stratified by PCP status, there were no
significant differences in screening rates for hepatitis
C (93% of those with a PCP, 94% of those without
https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss2/5
DOI: 10.46804/2641-2225.1133

P value

<.001

a PCP; P = .545), HIV (88% of those with a PCP,
82% of those without a PCP; P = .972), or hepatitis
A immunity (62% of those with a PCP, 48% of those
without a PCP; P = .231). Hepatitis C infections
were common (75%, n = 76) among the cohort and
not associated with PCP status. HIV infection was
uncommon (1%, n = 1). Ever discussing PrEP with
a health care provider was rare (7%), regardless
of PCP status. However, 24 (24%) of participants
reported being somewhat or very willing to take a
daily pill to prevent HIV (Table 2).
When stratified by status of hepatitis B vaccination,
there were no significant differences in
demographics or health characteristics (Table 3).
In the multivariable analysis (Table 4), participants
with a PCP had 3.59 times higher odds of having
completed a full course of a hepatitis B vaccination
versus those without a PCP (95% CI, 1.28-7.59;
P = .014).
4
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Total, No. (%)
PCP, No. (%)
Without PCP, No. (%)

P value*

(N = 101)

(n = 68)

(n = 33)

<30 days

NA

26 (38)

NA

<12 months

NA

25 (37)

NA

12+ months

NA

7 (10)

NA

NA

10 (15)

NA

Cost/Insurance

NA

NA

17 (52)

Location

NA

NA

5 (15)

Felt judged in past

NA

NA

9 (27)

67 (66)

49 (72)

18 (55)

.081

Yes

61 (60)

49 (72)

12 (36)

.001

No

40 (40)

19 (28)

21 (67)

Yes

94 (93)

63 (93)

31 (94)

No

5 (5)

4 (6)

1 (3)

Unknown

2 (2)

1 (1)

1 (3)

Yes

76 (75)

49 (72)

27 (82)

No

25 (25)

19 (28)

6 (18)

Yes

53 (52)

42 (62)

11 (33)

No

47 (47)

25 (37)

22 (67)

1 (1)

1 (1)

0

8 (8)

4 (6)

4 (12)

Last saw PCP

Unknown
Reason for no PCP

--

†

Ever used a syringe service program

--

Ever received outpatient medication for addiction treatment

Ever had a hepatitis C test
.545

Known hepatitis C exposed or infected

Completed hepatitis B vaccination

Unknown
Known hepatitis B infection

‡

Completed hepatitis A vaccination

.286

.006

.433
.231

Yes

58 (57)

42 (62)

16 (48)

No

41 (41)

25 (37)

16 (48)

Unknown

2 (2)

1 (1)

1 (3)

1

0

1

--

Ever had HIV test

86 (85)

60 (88)

27 (82)

.370

HIV-positive

1 (1)

1 (1)

0

8 (8)

6 (9)

2 (6)

--

24 (24)

16 (24)

8 (24)

.937

77 (76)

52 (76)

25 (76)

Known hepatitis A infection
HIV status

Ever discussed PrEP with a health care provider
Pill daily HIV scale
Willing
Neutral/Unwilling
Published
by MaineHealth Knowledge Connection, 2022

Abbreviations: NA, not applicable; PCP, primary care provider; PrEP, pre-exposure prophylaxis. *Not calculated for variables with low frequencies
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Table 3. Descriptive Analysis of Study Population Stratified by Hepatitis B Vaccination

Total,
No. (%)
(n = 100)*
PCP status
Has PCP
67 (67)
No PCP
33 (33)
Age <40 y
72 (72)
†
Self-identified gender
Female
56 (56)
Male
44 (44)
Insurance status
Has insurance
73 (73)
No insurance
25 (25)
Rurality
Rural (isolated and small
18 (18)
rural)
Urban (large rural and
82 (82)
metropolitan)
Homelessness
Yes
45 (45)
No
55 (55)
Ever used a syringe service
program
Yes
66 (66)
No
34 (34)
Known hepatitis C exposed or
infected
Yes
75 (75)
No
25 (25)
Ever received outpatient
medication for addiction
treatment
Yes
60 (60)
No
40 (40)
Abbreviations: PCP, primary care provider.

With hepatitis B
vaccination,
No. (%)
(n = 53)

Without
hepatitis B
vaccination,
No. (%)
(n = 47)

42 (79)
11 (21)
38 (72)

25 (53)
22 (47)
34 (72)

32 (60)
21 (40)

24 (51)
23 (49)

.349

39 (74)
12 (23)

34 (72)
13 (28)

.639

11 (21)

7 (15)

42 (79)

P value
.006
.943

.603

40 (85)

24 (45)
29 (55)

21 (45)
26 (55)

39 (74)
14 (26)

27 (57)
20 (43)

40 (75)
13 (25)

35 (74)
12 (26)

32 (60)
21 (40)

28 (60)
19 (40)

.952

.089

.908

.935

*Any data that does not add to N =101 is due to missing data.
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Table 4. Logistic regression analysis between hepatitis B vaccination and potential predictors
Predictor variable

Unadjusted OR

P value

Primary care provider
Age <40 years
Ever used syringe service program
Insurance status

3.36 (1.40-8.08)
0.97 (0.40-2.32)
2.06 (0.89-4.78)
1.24 (0.50-3.09)

.007
.943
.091
.640

DISCUSSION
Among this cohort of PWID hospitalized in Maine
with injection-related infections, the proportion
of participants with a PCP (67%) and a PCP visit
in the past 12 months (51%) is comparable to
rates seen in prior literature. In a survey of PWID
recruited from several SSPs in Massachusetts,
60% of respondents saw their PCP in the past
year.10 Based on a 2018 study of health care use
among PWID, 53% of patients residing in Medicaid
expansion states reported having a usual source of
health care.19 Notably, Maine expanded Medicaid
around the time that this study began enrollment.
This expansion may have contributed to a greater
number of participants with PCPs than we
anticipated, given that cost and insurance issues
were among the top-cited reasons for not having a
PCP among participants in this study.
Although hepatitis B vaccination was the only
preventive care measure that was significantly
more common among participants with PCPs than
those without PCPs, only 60% of those with PCPs
confirmed receiving the vaccine at a PCP office.
Although recall bias could play a role, particularly
for those who may have received hepatitis B
vaccination in infancy, having a PCP may reflect
motivation to engage in preventive care.
Many strategies have been described and evaluated
for improving rates of hepatitis B vaccination among
PWID. In a targeted vaccination program for PWID in
the Netherlands, factors associated with completing
hepatitis B vaccination included administration
at addiction care centers and flexibility in vaccine
location for subsequent doses.20-21 Other promising
strategies include providing financial incentives
for vaccination, using accelerated vaccination
schedules, and offering peer interventions.6,21 In
recent years, the state health department in Maine
had a program that identified patients were eligible
for hepatitis B vaccination and called their PCPs
Published by MaineHealth Knowledge Connection, 2022

Multivariableadjusted OR
3.59 (1.30-9.94)
0.89 (0.350-2.26)
1.91 (0.780-4.68)
0.62 (0.206-1.85)

P value
.014
.806
.157
.390

to encourage offering hepatitis B vaccination. This
program also partnered with community-based
organizations in high-prevalence counties.22 This
program is an encouraging example of local health
care and public health partnerships that address
this need for preventive care.12 We hope that the
unprecedented innovations and collaborations
underway to promote COVID-19 vaccination will
create infrastructure and momentum for vaccination
and prevention campaigns for hepatitis B and other
infections.
Regarding other preventive care outcomes, almost
all participants had HIV and hepatitis C screening
at least once, regardless of PCP status. This finding
suggests that screening is successfully occurring in
settings outside PCP offices. Rates of hepatitis A
immunity were suboptimal at 47%. Although data
was not adequate to determine the contribution of
vaccine-derived immunity, this finding demonstrates
missed opportunities to vaccinate people at risk,
particularly given high rates of homelessness and
risk of hepatitis A exposure in shelters.3 Also, very
few participants have been offered PrEP, even
though a quarter reported willingness to take a daily
pill to prevent HIV. Any PCP can prescribe PrEP,
though many are not confident in doing so. A survey
of trainees at this institution identified non-amenable
clinic workflows and preceptor unfamiliarity as
barriers to PrEP prescribing.23
Although barriers to accessing primary care should
be further explored and addressed, we should also
consider other strategies to provide preventive care
for people without PCPs. These strategies include
facilitating vaccination through offices that treat
opioid disorder, hospitals, SSPs, and jails because
the participants in this study heavily interacted with
these settings. Though there have been successful
models of vaccination programs in correctional
facilities, as of 2020, the jail medical contractors in
Maine did not offer hepatitis vaccinations, despite
7
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promotion by state health department officials.22
There have also been successful models of
vaccination onsite at SSPs. One program in Alaska
that incentivized vaccination at $20 to $50 per shot
yielded higher vaccination rates than usual care,
with over 80% of patients completing 3 doses.24
The Centers for Disease Control and Prevention
suggests offering comprehensive and integrated
services. These service include outreach to facilitate
access to addiction treatment and preventive
services, supportive structures (eg, co-location
of services), and offering linkages to care upon
release from jail.17 The inpatient hospital setting
and medical respite facilities seem particularly well
suited to provide vaccinations to patients who need
prolonged medical care for their complex infections,
such as the participants in this study. Inpatient
vaccination is precedented and currently orderable
at our institution.
Notably, for all participants in this study, even those
who saw PCPs and/or received recommended
infectious disease vaccinations or screening,
the current systems did not prevent them from
becoming hospitalized with a serious invasive
infection. Harm reduction tools, such as education
on safer techniques for drug consumption, is a
critical part of infection prevention that should be
incorporated into health care settings alongside
other components, such as vaccinations.
This study has several limitations. First, we were
unable to capture the timing and frequency of
preventive care receipt, which is an important
component of screening. Second, the data
collection did not capture whether the participants
with PCPs had discussed their drug use with their
PCPs. Third, the reasons for not engaging in
preventive care were not explored. It is possible that
participants were offered but declined preventive
services, for example, due to time constraints.
Fourth, the data points available to determine
prior exposure to hepatitis B were limited (no core
antibody was available). This limitation may have
affected assignment of vaccination status, though
we have no reason to believe that this limitation
would have a differential effect based on PCP
status. Fifth, there was insufficient data to determine
the location or timing of hepatitis B vaccination
administration. Some participants born after 1991
may have received hepatitis B vaccination as
children. We attempted to address this limitation
by adjusting for age in the multivariate analysis.25
https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss2/5
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Finally, we were unable to examine other important
preventive measures for this population (eg,
other vaccinations, sexually transmitted infection
screening and education, tuberculosis screening,
overdose prevention).

CONCLUSIONS
Many PWID who were hospitalized in Maine for
invasive infections have received primary and
preventive care. In our study, having a PCP was
associated with receiving hepatitis B vaccination.
However, there are still missed opportunities to fill
in gaps in preventive care in PCP and non-PCP
settings. Further research on PCP use among
PWID in Maine should explore patients’ cost
concerns and reasons for not receiving preventive
services in the primary care setting. Although this
goal of optimizing primary care access and use is
being pursued, health care facilities and community
settings in Maine should partner to provide
recommended vaccinations and other preventive
services for PWID throughout Maine’s communities.
Conflicts of interest: None
Funding: This research was supported by grant
U54 GM115516 from the National Institutes of
Health for the Northern New England Clinical and
Translational Research Network.
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